InnFocus, Inc. has raised $33.9 million in Series C financing to further develop its InnFocus MicroShunt glaucoma drainage system to treat early, moderate, and late stage primary open angle glaucoma. The company has stated that the final phase of its FDA clinical trials will begin in January, 2016.
What makes InnFocus’ work significant is that it is reportedly the only company with a sponsored prospective randomized study that compares a device to the trabeculectomy procedure, the praised standard treatment for glaucoma that’s been around for decades. The InnFocus MicroShunt system helps effectively drain eye fluid and reduces intraocular pressure that prevents the progression of glaucoma and vision loss without the need for surgery.
The implant is a very small micro-tube, about the size of an eyelash, that is soft and conforms to the eye, which pushes the aqueous fluid out of the anterior chamber of the eye and only takes 15 minutes to perform.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
More than 250 patients have now been treated with the InnFocus MicroShunt device in Canada, France, Japan, the Netherlands, Spain, Switzerland, the Dominican Republic, and the U.S., which was was developed in collaboration with the University of Miami’s Miller School of Medicine, Bascom Palmer Eye Institute.
Photo: Screenshot from InnFocus
